The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1L3X97     2-[2-[(1-carboxylato-2- sulfido...

This record was replaced with 123770.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC254031


High impact information on NSC254031

  • Using appropriate linear regression analysis, ERPF could be estimated by the two- and one-sample 99mTc-L,L-EC clearance with an error of 24.2 and 22.8 ml/min, respectively [4].
  • 99mTc-L,L-EC has a very low plasma protein binding (31% +/- 6.8%) as compared to 99mTc-MAG3 (88% +/- 5.2%) and a larger volume of distribution [5].
  • A variety of 99mTc-labelled agents is now available or in clinical evaluation for the study of brain perfusion (99mTc-labelled HMPAO, ECD, MRP20), myocardial perfusion (99mTc-labelled MIBI, teboroxime and phosphines) and renal function (99mTc-MAG3, 99mTc-L,L-EC) [6].
  • Eighty-two patients (39 females, 43 males), including 31 children, with a mean age of 33.4+/-11.3 years (range, 4 months to 74 years), underwent both 99mTc-DMSA and 99mTc-L,L-EC scintigraphy within a period of 14 days [7].
  • 99Tcm-bicisate (99Tcm-ECD), often used as a brain perfusion agent, is rapidly converted following intravenous injection to the polar monoacid (99Tcm-ECM) and diacid (99Tcm-EC) metabolites [8].

Chemical compound and disease context of NSC254031


Associations of NSC254031 with other chemical compounds


Analytical, diagnostic and therapeutic context of NSC254031


  1. Clinical evaluation of technetium-99m-L,L-ethylenedicysteine in patients with chronic renal failure. Prvulovich, E.M., Bomanji, J.B., Waddington, W.A., Rudrasingham, P., Verbruggen, A.M., Ell, P.J. J. Nucl. Med. (1997) [Pubmed]
  2. The use of 99Tcm-EC for captopril test in patients with hypertension. Kostadinova, I., Simeonova, A. Nuclear medicine communications. (1995) [Pubmed]
  3. Renovascular hypertension due to Takayasu's arteritis demonstrated by Tc-99m ethylenedicysteine captopril scintigraphy. Uğur, O., Peksoy, I., Caner, B., Cekirge, S., Balkanci, F., Bekdik, C. Clinical nuclear medicine. (1996) [Pubmed]
  4. Technetium-99m L,L-ethylenedicysteine clearance and correlation with iodine-125 orthoiodohippurate for the determination of effective renal plasma flow. Stoffel, M., Jamar, F., Van Nerom, C., Verbruggen, A., Besse, T., Squifflet, J.P., Beckers, C. European journal of nuclear medicine. (1996) [Pubmed]
  5. First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent. Van Nerom, C.G., Bormans, G.M., De Roo, M.J., Verbruggen, A.M. European journal of nuclear medicine. (1993) [Pubmed]
  6. Radiopharmaceuticals: state of the art. Verbruggen, A.M. European journal of nuclear medicine. (1990) [Pubmed]
  7. Technetium-99m-L,L-ethylenedicysteine renal scan as a single-modality investigation for the evaluation of renal morphology and function: a comparative study with technetium-99m-dimercaptosuccinic acid. Narayana, C., Tripathi, M., Kumar, A., Gowda, N.K., Phom, H., Chandra, P., Bandopadhyaya, G., Bal, C. Nuclear medicine communications. (2004) [Pubmed]
  8. Evaluation of 99Tcm-bicisate as a renal imaging agent. Ozker, K., Kabasakal, L., Liu, Y., Hellman, R.S., Isitman, A., Krasnow, A.Z., Collier, B.D. Nuclear medicine communications. (1997) [Pubmed]
  9. Comparison of Tc-99m EC and Tc-99m DTPA captopril scintigraphy to diagnose renal artery stenosis. Uğur, O., Serdengeçti, M., Karaçalioğlu, O., Peksoy, I., Cekirge, S., Aslan, N., Ergün, E.L., Duranay, M., Yurdakul, M., Caner, B., Bayhan, H. Clinical nuclear medicine. (1999) [Pubmed]
  10. Effectiveness of diuretic injection on the measurement of differential renal function using Tc-99m DMSA in patients with a dilated renal pelvis. Buyukdereli, G., Guney, I.B., Seydaoglu, G. Clinical nuclear medicine. (2005) [Pubmed]
  11. Evaluation of technetium-99m-L,L-EC in renal transplant recipients: a comparative study with technetium-99m-MAG3 and iodine-125-OIH. Stoffel, M., Jamar, F., Van Nerom, C., Verbruggen, A., Mourad, M., Leners, N., Squifflet, J.P., Beckers, C. J. Nucl. Med. (1994) [Pubmed]
  12. Technetium-99m-L,L-ethylenedicysteine scintigraphy in patients with renal disorders. Gupta, N.K., Bomanji, J.B., Waddington, W., Lui, D., Costa, D.C., Verbruggen, A.M., Ell, P.J. European journal of nuclear medicine. (1995) [Pubmed]
  13. Technetium-99m-EC and other potential new agents in renal nuclear medicine. Moran, J.K. Seminars in nuclear medicine. (1999) [Pubmed]
WikiGenes - Universities